P380 Early improvement of endoscopic outcomes with risankizumab is associated with reduced hospitalisation and surgery rates in patients with Crohn’s disease
Feagan, B.G.(1);Colombel, J.F.(2);Panaccione, R.(3);Schreiber, S.(4);Ferrante, M.(5);Kamikozuru, K.(6);Lee, W.J.(7);Griffith, J.(7);Kligys, K.(7);Kalabic, J.(8);Chen, N.(7);Dubinsky, M.(2);
(1)Western University- Alimentiv Inc., n/a, London, Canada;(2)Icahn School of Medicine at Mt. Sinai, n/a, New York, United States;(3)University of Calgary, n/a, Calgary, Canada;(4)University Hospital Schleswig-Holstein, n/a, Kiel, Germany;(5)University Hospital Leuven, n/a, Leuven, Belgium;(6)Hyogo College of Medicine, n/a, Nishinomiya, Japan;(7)AbbVie Inc., n/a, North Chicago, United States;(8)AbbVie Deutschland GmbH & Co. KG, n/a, Ludwigshafen, Germany;
Control of endoscopic inflammation like endoscopic remission is an important treatment target in Crohn’s disease (CD), as suggested in the STRIDE II guidelines. This study evaluated the relationship of early improvement in endoscopic outcomes on hospitalisation and surgery rates at 52 wks in patients with CD treated with risankizumab (RZB).
This post-hoc analysis uses data from three double-blind, randomised Phase 3 induction (ADVANCE and MOTIVATE) and maintenance (FORTIFY) trials evaluating the efficacy and safety of RZB in patients with moderate to severe CD. Patients who responded to 12-wk induction therapy with RZB IV (600 mg or 1200mg) in ADVANCE or MOTIVATE and received up to 52 wks of maintenance therapy with RZB SC (180 mg or 360 mg) in FORTIFY were analysed. Incidence rates (events/100 person-years) of CD-related hospitalisation, CD-related surgery (surgical procedures due to adverse events or complications related to CD), all-cause hospitalisation, and all-cause surgery were evaluated from the beginning of maintenance to wk 52 and compared between patients who achieved endoscopic outcomes at end of induction (wk 12) and those who did not. Endoscopic response, endoscopic remission and ulcer-free endoscopy (absence of ulceration) were defined using the Simple Endoscopic Score for CD (SES-CD) (Figure 1-3), as scored by a blinded central reviewer.
A total of 298 patients were included in the analyses. Patients who achieved endoscopic response (n=121) at wk 12 had a significantly reduced incidence rate of CD-related hospitalisation, CD-related surgery, and all-cause hospitalisation by wk 52 compared to those who did not achieve an endoscopic response (n=177) at wk 12 (Figure 1). Additionally, patients who achieved endoscopic remission at wk 12 (n=83) had a significantly reduced incidence rate of CD-related hospitalisation, CD-related surgery, and all-cause hospitalisation by wk 52, compared to those not achieving endoscopic remission at wk 12 (n=215) (Figure 2). Though not statistically significant, numerically lower rates of all-cause surgery were observed for patients who achieved endoscopic remission or endoscopic response at wk 12. Significantly lower rates of CD-related hospitalisation, CD-related surgery, all-cause hospitalisation, and all-cause surgery by wk 52 were observed among patients who achieved ulcer-free endoscopy (absence of ulceration) (n=70) vs those who did not (n=228) at wk 12 (Figure 3).
Early improvement of endoscopic outcomes at wk 12 is associated with significant reductions in hospitalisations and surgeries through 52 wks for patients receiving RZB therapy.